Mounjaro vs Zepbound: Same Drug, Different FDA Labels, Very Different Goals

What Is the Difference Between Mounjaro and Zepbound?

Mounjaro and Zepbound are the same molecule dispensed under two brand names with two separate FDA approvals. Tirzepatide is the active ingredient in both. Mounjaro received FDA approval for type 2 diabetes management in May 2022, and Zepbound received a separate approval for chronic weight management in adults with a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related condition such as hypertension, dyslipidemia, or obstructive sleep apnea, in November 2023 [1][2].

The injector pens, dose increments (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg), and the once-weekly subcutaneous injection schedule are identical across brands. The labels diverge in their approved indications, required clinical documentation for insurers, and the patient populations studied in the key trials.

Prescribers sometimes write Mounjaro for weight loss in patients who do not have diabetes. That is an off-label use. Conversely, a patient with both type 2 diabetes and obesity might qualify for either brand depending on their insurer's rules. The practical choice is often driven by formulary placement rather than clinical pharmacology, because the pharmacology is the same.

Eli Lilly priced both at approximately $1,060 per month at list price as of early 2025, though Lilly's savings card program can reduce out-of-pocket costs for commercially insured patients to as low as $25 per month for Zepbound.

How Tirzepatide Works Differently Than Semaglutide

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide acts on GLP-1 receptors only. This mechanistic difference likely explains a meaningful portion of the larger weight-loss numbers seen in tirzepatide trials.

GLP-1 receptor activation slows gastric emptying, reduces appetite, and potentiates glucose-dependent insulin secretion. GIP receptor activation amplifies insulin secretion through a separate pathway and may also act directly on adipose tissue to alter fat storage, though the exact adipose mechanism is still being studied. The combination appears to produce additive metabolic effects that exceed either pathway alone.

This dual mechanism does not change the side-effect profile in a clinically dramatic way. Both drug classes share nausea, vomiting, diarrhea, and constipation as the most common adverse effects, and both carry a boxed warning for a potential risk of thyroid C-cell tumors observed in rodents (not confirmed in humans at approved doses). The Zepbound FDA label notes that the drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [2].

SURMOUNT-1 vs STEP-1: The Weight-Loss Numbers That Define This Conversation

The head-to-head data that patients and prescribers most often request comes from comparing two separate phase 3 programs: SURMOUNT (tirzepatide) and STEP (semaglutide).

In SURMOUNT-1 (N=2,539), adults without diabetes who received tirzepatide 15 mg lost a mean of 22.5% of body weight at 72 weeks compared with 2.4% for placebo (P<0.001) [3]. Participants on 10 mg lost 21.4% and those on 5 mg lost 16.0%. Roughly 57% of participants on 15 mg achieved at least 20% weight loss.

In STEP-1 (N=1,961), semaglutide 2.4 mg (Wegovy) produced mean weight loss of 14.9% at 68 weeks versus 2.4% placebo (P<0.001) [4]. Approximately 32% of participants lost 20% or more of body weight.

Those numbers are not directly comparable because the trials enrolled different populations, used different durations, and ran in different time periods. No randomized, controlled head-to-head trial between semaglutide 2.4 mg and tirzepatide for weight loss has been published as of early 2025. What exists is SURPASS-2, a head-to-head in type 2 diabetes patients, where tirzepatide 15 mg produced 12.4 kg weight loss versus 8.5 kg with semaglutide 1.0 mg (Ozempic dose, not the higher Wegovy dose) [5].

The clinical takeaway: tirzepatide appears to produce greater mean weight loss than semaglutide at their respective approved doses, but individual response varies considerably. A patient who responds well to semaglutide may have little reason to switch.

Wegovy vs Zepbound: Which Has Better Cardiovascular Evidence?

For patients with established cardiovascular disease, the evidence currently favors semaglutide because longer-duration cardiovascular outcome data exist.

The SELECT trial (N=17,604) showed that semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% relative to placebo over a median follow-up of 34.2 months in adults with overweight or obesity and pre-existing cardiovascular disease but without diabetes [6]. The Wegovy FDA label was updated in March 2024 to include this cardiovascular risk reduction indication, making Wegovy the first weight-loss medication approved to reduce MACE [1].

As of early 2025, no equivalent cardiovascular outcome trial for tirzepatide in people with obesity has completed and reported. The SURPASS-CVOT trial is ongoing and will address this gap for patients with type 2 diabetes. The SURMOUNT-MMO trial is investigating cardiovascular outcomes specifically in people with obesity and established cardiovascular disease, but results are not yet available.

For a patient whose primary clinical concern is reducing cardiovascular risk, and who has overweight or obesity with pre-existing heart disease, Wegovy has a data advantage that Zepbound currently cannot match.

Ozempic vs Wegovy: Why the Same Molecule Comes in Two Doses

Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg) is FDA-approved for type 2 diabetes and, since August 2021, carries an additional cardiovascular risk-reduction indication in adults with type 2 diabetes and established cardiovascular disease. Wegovy is semaglutide at the 2.4 mg weekly dose, approved specifically for chronic weight management.

The dose difference matters. The 2.4 mg dose in Wegovy was selected because STEP trials demonstrated a dose-response relationship. STEP-2 (N=1,210, type 2 diabetes patients) showed semaglutide 2.4 mg produced 9.6% body weight loss versus 6.9% at 1.0 mg and 3.4% for placebo at 68 weeks [7].

Prescribers sometimes write Ozempic off-label for weight loss because it has been on the market longer, has more formulary coverage for patients with diabetes, and was historically easier to obtain during the Wegovy shortage periods that began in 2022. Off-label use of Ozempic for weight loss is not supported by the label and delivers a lower maximum dose than Wegovy. Patients seeking the full approved weight-management dose should receive Wegovy or a compounded semaglutide preparation from a licensed 503B outsourcing facility during shortage periods, under explicit prescriber direction.

GLP-1 vs Phentermine: Short-Term Tool vs Long-Term Treatment

Phentermine is a sympathomimetic amine that suppresses appetite by increasing norepinephrine release in the hypothalamus. The FDA approved it for short-term obesity management in 1959, and its approved duration is generally 12 weeks.

GLP-1 receptor agonists and dual GIP/GLP-1 agonists like tirzepatide are approved for long-term chronic use. SURMOUNT-4 (N=670) demonstrated that patients who completed 36 weeks of tirzepatide open-label lead-in and then continued the drug maintained 5.5% additional weight loss at 88 weeks total, while those who were switched to placebo regained a mean of 14.8 percentage points of body weight [8]. This rebound on discontinuation is consistent with what was observed in STEP-4 (semaglutide) and underscores that obesity is a chronic condition requiring ongoing pharmacotherapy for most patients.

Phentermine is cheaper (often under $30 per month generic) and produces modest short-term results. The American Association of Clinical Endocrinology (AACE) guidelines recommend GLP-1-based agents as preferred pharmacotherapy for obesity given their superior weight-loss magnitude, tolerability profile, and cardiometabolic benefits [9]. Phentermine combinations (phentermine/topiramate ER, brand name Qsymia) remain a lower-cost option with roughly 7.5% to 9.8% placebo-subtracted weight loss at 56 weeks, substantially below tirzepatide's effect size.

Dosing Schedules and Titration: What Patients Actually Experience

Both Mounjaro/Zepbound and Wegovy use a slow dose escalation to reduce gastrointestinal side effects. The titration schedules differ slightly.

For tirzepatide (Mounjaro or Zepbound), the starting dose is 2.5 mg once weekly for 4 weeks, then 5 mg for 4 weeks, with additional 2.5 mg increases every 4 weeks as tolerated up to a maximum of 15 mg per week [2]. The 2.5 mg starting dose is sub-therapeutic and exists solely for tolerability.

For semaglutide 2.4 mg (Wegovy), patients start at 0.25 mg once weekly for 4 weeks, increase to 0.5 mg for 4 weeks, then 1 mg for 4 weeks, 1.7 mg for 4 weeks, and reach the full 2.4 mg maintenance dose at week 17 [1]. The slower titration produces a similar nausea incidence to tirzepatide, with most GI side effects concentrated in the early weeks.

SURMOUNT-3 (N=806) took a different approach: participants completed an intensive lifestyle intervention for 12 weeks before randomization to tirzepatide or placebo. Mean weight loss from lifestyle run-in was 6.9%. From randomization, tirzepatide 15 mg produced an additional 18.4% weight loss at 72 weeks, for a total of 24.3% from original body weight [10]. That figure represents the upper boundary of what tirzepatide can achieve when behavioral support is layered on top.

Who Should Take Which Drug: A Clinical Decision Framework

The following framework reflects how HealthRX clinicians approach the Mounjaro/Zepbound/Wegovy/Ozempic decision in a new patient consultation. It is not a substitute for individual clinical judgment.

Step 1. Confirm the primary indication. If the patient has type 2 diabetes and the prescriber wants a GLP-1-class drug for glycemic control, both Ozempic and Mounjaro are on-label. For glycemic benefit plus maximum weight loss, SURPASS-2 data support tirzepatide's superiority over semaglutide 1 mg. If the patient has obesity without diabetes and the goal is weight management, Wegovy or Zepbound are the on-label options.

Step 2. Assess cardiovascular history. Patients with established atherosclerotic cardiovascular disease and obesity benefit from SELECT-level evidence. Prescribe Wegovy (or Ozempic in T2D with CVD) when a proven cardiovascular endpoint reduction is a primary treatment goal and tirzepatide cardiovascular outcome data are not yet available.

Step 3. Check the formulary. Insurance coverage varies dramatically by employer plan and payer. Many commercial plans exclude obesity drugs entirely. Medicare Part D was prohibited from covering obesity drugs until recently, and coverage under the Inflation Reduction Act changes is being phased in. Prior authorization requirements differ: Mounjaro requires a diabetes diagnosis code; Zepbound requires obesity or overweight-plus-comorbidity documentation. Prescribers who write Mounjaro for weight loss in a non-diabetic patient are inviting a denial.

Step 4. Consider the patient's prior GLP-1 experience. A patient who previously tried semaglutide and lost <5% body weight after 12 weeks at maximum tolerated dose might reasonably switch to tirzepatide, given the different receptor profile and consistently higher effect sizes in trials. No published trial currently guides this cross-class switch decision, but clinical consensus supports attempting it.

Step 5. Discuss maintenance expectations. Both STEP-4 (semaglutide) and SURMOUNT-4 (tirzepatide) data show substantial weight regain after discontinuation. The Endocrine Society's 2023 clinical practice guideline on pharmacological management of obesity states: "Pharmacological therapy for obesity should be considered a long-term intervention, and clinicians should counsel patients that weight regain is expected when medication is discontinued" [11]. Setting this expectation before starting therapy reduces dropout when patients assume a finite course of treatment.

Side Effects and Contraindications: What the Labels Actually Say

The most common adverse effects across tirzepatide and semaglutide trials are gastrointestinal. In SURMOUNT-1, nausea occurred in 30.5% of patients receiving tirzepatide 15 mg versus 6.1% on placebo [3]. Diarrhea occurred in 22.8% versus 6.4%. The majority of events were mild to moderate and declined after the first 12 weeks.

In STEP-1, nausea occurred in 44.2% of semaglutide recipients versus 15.5% on placebo, and vomiting in 24.5% versus 5.9% [4]. The higher reported nausea incidence in STEP-1 versus SURMOUNT-1 may reflect differences in trial methodology and patient populations as much as true pharmacological differences.

Both drug classes share a contraindication for personal or family history of medullary thyroid carcinoma or MEN2. Both carry warnings about pancreatitis, acute gallbladder disease (the incidence of cholelithiasis in STEP-1 was 1.6% on semaglutide vs 0.7% on placebo), and acute kidney injury secondary to dehydration from GI losses.

Tirzepatide does not carry an approved indication in pregnancy; both the Mounjaro and Zepbound labels recommend discontinuation at least 2 months before a planned pregnancy due to the long half-life and theoretical fetal risk at therapeutic doses [2].

Cost, Compounding, and Access

List prices for Wegovy, Zepbound, and Mounjaro are approximately $1,000 to $1,300 per month without insurance as of early 2025. Ozempic carries a list price of roughly $935 per month for the 2 mg pen.

During FDA-designated shortage periods, compounding pharmacies licensed as 503A or 503B facilities have legally dispensed compounded tirzepatide and semaglutide. The FDA removed semaglutide from the drug shortage list in February 2024 for Wegovy, and removed tirzepatide from the shortage list in December 2024 after confirming adequate supply from Eli Lilly. Compounded versions of these drugs are no longer legally permissible at currently licensed 503A pharmacies under FDA guidance, though enforcement timelines have shifted. Patients currently receiving compounded tirzepatide or semaglutide should consult their prescriber about transitioning to the FDA-approved commercial products.

Manufacturer savings programs: Novo Nordisk's Wegovy savings card allows eligible commercially insured patients to pay as little as $0 to $25 per month. Eli Lilly's Zepbound savings card caps out-of-pocket at $25 to $550 per month depending on insurance status. Uninsured patients without savings card eligibility face the full list price.

The AACE/ACE obesity clinical practice guidelines recommend that cost and access barriers be addressed explicitly in the treatment plan, recognizing that inability to afford long-term pharmacotherapy substantially increases cardiometabolic risk at the population level [9].